This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 11 trials Clear all
Filter by:

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Non-Hodgkin
    Lymphoma, Non-Hodgkin
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Fludarabine, Drug: Cyclophosphamide, Drug: JCAR017

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Fludarabine, Drug: Cyclophosphamide, Drug: JCAR017

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UCLA Medical Centre-Santa Monica, Santa Monica, California, United States

Brief Summary

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: - Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; - Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; - Posttreatment, which includes follow-up assessments for disease status and safety for 2 years.

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma,...
    Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma,...
  • Phase Phase 2
    Phase 2
INTERVENTION

Biological: lisocabtagene maraleucel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: lisocabtagene maraleucel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Brief Summary

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell
    Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: JCAR017 (lisocabtagene maraleucel), Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib, Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: JCAR017 (lisocabtagene maraleucel), Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib, Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

  • Status Recruiting
    Recruiting
  • Condition Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hod...
    Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hod...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: JCAR017, Drug: Lymphodepleting, Drug: Fludarabine, Drug: Cyclophosphamide

Eligibility
  • Ages: up to 25 / (18 to 64 years)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: JCAR017, Drug: Lymphodepleting, Drug: Fludarabine, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brief Summary

This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL. Phase 1 will identify a recommended Phase 2 dose (RP2D). Phase 2 will evaluate the efficacy of JCAR017 RP2D in the following three disease cohorts: Cohort 1 (r/r B-ALL), Cohort 2 (MRD+ B-ALL) and Cohort 3 (r/r B-NHL, [DLBCL, BL, or PMBCL]). A Simon's Optimal two-stage study design will be applied to Cohort 1 and 2 in Phase 2.

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Non-Hodgkin
    Lymphoma, Non-Hodgkin
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: JCAR017

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: JCAR017

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Austria

Brief Summary

This open-label Phase 2 study will evaluate the safety and efficacy of modified T cells (JCAR017) administered to adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The study will also help determine how long the modified T cells stay in the patient's body. Furthermore, changes in the patient's quality of life will be described. Phase 2 (autologous T cells expressing anti-CD19 chimeric antigen receptor) (DLBCL NOS [de novo or tFL], follicular lymphoma Grade 3B [FL3B], high grade B-cell Lymphoma [HGBL] and primary central nervous system lymphoma [PCNSL]).

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Larg...
    Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell, Lymphoma, Larg...
  • Phase Phase 2
    Phase 2
INTERVENTION

Biological: lisocabtagene maraleucel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: lisocabtagene maraleucel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Cedars-Sinai Medical Group, Los Angeles, California, United States

Brief Summary

This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma,...
    Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma,...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: JCAR017, Drug: Durvalumab, Drug: CC-122, Drug: Ibrutinib, Drug: CC-220, Drug: Relatlimab, Drug: Nivolumab, Drug: CC-99282

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: JCAR017, Drug: Durvalumab, Drug: CC-122, Drug: Ibrutinib, Drug: CC-220, Drug: Relatlimab, Drug: Nivolumab, Drug: CC-99282

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope National Medical Center, Duarte, California, United States

Brief Summary

This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested: Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

  • Status Recruiting
    Recruiting
  • Condition Primary Mediastinal B-cell Lymphoma, Mantle-cell Lymphoma, Diffus...
    Primary Mediastinal B-cell Lymphoma, Mantle-cell Lymphoma, Diffus...
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule, Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule, Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama-Birmingham, Birmingham, Alabama, United States

Brief Summary

This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment.

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Lymphoma, Non-Hodgkin
    Lymphoma, Non-Hodgkin
  • Phase Phase 3
    Phase 3
INTERVENTION

Drug: Standard of Care, Genetic: JCAR017

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Standard of Care, Genetic: JCAR017

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Virginia G Piper Cancer Center, Scottsdale, Arizona, United States

Brief Summary

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm A) or to receive JCAR017 (Arm B). All subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event. Subjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

  • Status Available
    Available
  • Condition Lymphoma, Large B-Cell, Diffuse
    Lymphoma, Large B-Cell, Diffuse
  • Phase N/A
    N/A
INTERVENTION

Biological: Nonconforming Lisocabtagene Maraleucel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Biological: Nonconforming Lisocabtagene Maraleucel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States

Brief Summary

This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The expanded access protocol will be used to allow subjects to receive nonconforming lisocabtagene maraleucel only if the potential benefit is better than the potential risk. This expanded access protocol is restricted to those subjects who were prescribed lisocabtagene maraleucel as part of their routine care. Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with nonconforming lisocabtagene maraleucel as the treatment plan.